Literature DB >> 12001127

Prognostic relevance of cell biologic and biochemical features in conventional chondrosarcomas.

Thomas Aigner1, Susanna Müller, Daniel Neureiter, Duane M Illstrup, Thomas Kirchner, Johannes Björnsson.   

Abstract

BACKGROUND: Conventional chondrosarcoma is the second most common malignant solid tumor of bone, and its management still poses a challenge for the orthopedic surgeon. Currently, tumor grade is the only parameter of prognostic significance besides stage and, possibly, resection margins. Additional independent prognostic markers therefore would be highly valuable for patient management.
METHODS: In the current study, the authors evaluated biologic markers for various chondrocytic phenotypes by histochemical and immunohistochemical technology in a large series of clinically well defined cases of enchondromas and conventional chondrosarcomas, each with at least 5 years of clinical follow-up.
RESULTS: The authors' results confirm the strong correlation between clinical behavior and cell differentiation as expressed by marker genes. The phenotypes of the tumor cells are the biologic substrate of the histopathologic appearance of the neoplasms and, thus, the biologic basis for classic tumor grading. Collagen Types II and X, as well as the proteoglycan aggrecan, suggest a mature neoplastic phenotype and good prognosis, i.e., low recurrence rate, rare metastasis, and long survival. Conversely, collagen Type I, together with cell spindling, indicates a transition to a more proliferative, so-called "dedifferentiated" phenotype, which clearly is associated with a poorer prognosis. The changes in cellular phenotypes are accompanied by changes in proliferative activity. Thus, low-grade neoplasms showing mainly mature and terminally differentiated (hypertrophic) chondrocytes display only scant proliferation whereas less differentiated chondrosarcomas with biologically dedifferentiated chondrocytes show significantly higher proliferative activity, a feature that is also highly correlated with prognosis.
CONCLUSIONS: These data indicate that molecular markers are to a large extent the biologic basis of the conventional grading, rather than representing independent prognostic markers. The authors' results further indicate that COL1 has significant value in the distinction between enchondromas and low-grade chondrosarcomas including these that are histologically similar. Further understanding of chondrocytic phenotypes will be a promising way to provide new tumor markers for better understanding, diagnosis, and treatment of chondroid neoplasms. Copyright 2002 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12001127     DOI: 10.1002/cncr.10461

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  New cell lines with chondrocytic phenotypes from human chondrosarcoma.

Authors:  Ikuo Kudawara; Nobuhito Araki; Akira Myoui; Yoichi Kato; Atsumasa Uchida; Hideki Yoshikawa
Journal:  Virchows Arch       Date:  2004-04-29       Impact factor: 4.064

2.  Establishment and characterization of the permanent human cell line C3842 derived from a secondary chondrosarcoma in Ollier's disease.

Authors:  Thomas Kalinski; Sabine Krueger; Antje-Friederike Pelz; Peter Wieacker; Roland Hartig; Martin Röpke; Regine Schneider-Stock; Frank Dombrowski; Albert Roessner
Journal:  Virchows Arch       Date:  2005-02-25       Impact factor: 4.064

Review 3.  [Cartilage tumors. Classification, conditions for biopsy and histologic characteristics].

Authors:  G Delling; B Jobke; S Burisch; M Werner
Journal:  Orthopade       Date:  2005-12       Impact factor: 1.087

4.  Molecular basis of differentiation therapy for soft tissue sarcomas.

Authors:  Gaurav Luther; Richard Rames; Eric R Wagner; Gaohui Zhu; Qing Luo; Yang Bi; Stephanie H Kim; Jian-Li Gao; Enyi Huang; Ke Yang; Linyuan Wang; Xing Liu; Mi Li; Ning Hu; Yuxi Su; Xiaoji Luo; Liang Chen; Jinyong Luo; Rex C Haydon; Hue H Luu; Lan Zhou; Tong-Chuan He
Journal:  Trends Cancer Res       Date:  2010

5.  Expression of versican in relation to chondrogenesis-related extracellular matrix components in canine mammary tumors.

Authors:  I Erdélyi; A J A M van Asten; J E van Dijk; H Nederbragt
Journal:  Histochem Cell Biol       Date:  2005-09-29       Impact factor: 4.304

6.  In malignant cartilagenous tumors, immunohistochemical expression of procollagen PC1CP peptide is higher and that of PC2CP lower than in benign cartilaginous lesions.

Authors:  Camille Delaunay-Lemarie; Jean-Baptiste Vincourt; Béatrice Marie; Shyue-Fang Battaglia-Hsu; Stéphanie Etienne; François Sirveaux; Phi Linh Nguyen Thi; Jacques Magdalou; Jean-Michel Vignaud; Guillaume Gauchotte
Journal:  Virchows Arch       Date:  2015-06-23       Impact factor: 4.064

7.  Fluid shear promotes chondrosarcoma cell invasion by activating matrix metalloproteinase 12 via IGF-2 and VEGF signaling pathways.

Authors:  P Wang; S-H Chen; W-C Hung; C Paul; F Zhu; P-P Guan; D L Huso; A Kontrogianni-Konstantopoulos; K Konstantopoulos
Journal:  Oncogene       Date:  2014-12-01       Impact factor: 9.867

8.  Chondrosarcoma: with updates on molecular genetics.

Authors:  Mi-Jung Kim; Kyung-Ja Cho; Alberto G Ayala; Jae Y Ro
Journal:  Sarcoma       Date:  2011-02-15

9.  Microenvironment alters epigenetic and gene expression profiles in Swarm rat chondrosarcoma tumors.

Authors:  Christopher A Hamm; Jeff W Stevens; Hehuang Xie; Elio F Vanin; Jose A Morcuende; Hakeem Abdulkawy; Elisabeth A Seftor; Simone T Sredni; Jared M Bischof; Deli Wang; Sergey Malchenko; Maria de Fatima Bonaldo; Thomas L Casavant; Mary J C Hendrix; Marcelo B Soares
Journal:  BMC Cancer       Date:  2010-09-01       Impact factor: 4.430

10.  rAAV Vectors as Safe and Efficient Tools for the Stable Delivery of Genes to Primary Human Chondrosarcoma Cells In Vitro and In Situ.

Authors:  Henning Madry; Jagadeesh K Venkatesan; Gertrud Schmitt; Sarah Schetting; Myriam Ekici; Dieter Kohn; Magali Cucchiarini
Journal:  Sarcoma       Date:  2012-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.